Adaptive Biotechnologies Corp
$ 24.93
5.64%
07 Aug - close price
- Market Cap 3,753,807,000 USD
- Current Price $ 24.93
- High / Low $ 24.95 / 24.28
- Stock P/E N/A
- Book Value 0.90
- EPS -0.38
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.04 %
- ROE -0.39 %
- 52 Week High 24.96
- 52 Week Low 11.92
About
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company is headquartered in Seattle, Washington.
Analyst Target Price
$25.07
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-07-28 | 2026-05-05 | 2026-02-05 | 2025-11-05 | 2025-08-05 | 2025-05-01 | 2025-02-11 | 2024-11-07 | 2024-08-01 | 2024-05-07 | 2024-02-14 | 2023-11-09 |
| Reported EPS | -0.1 | -0.13 | -0.09 | -0.15 | -0.17 | -0.2 | -0.23 | -0.22 | -0.29 | -0.32 | -0.3 | -0.35 |
| Estimated EPS | -0.13 | -0.16 | -0.18 | -0.16 | -0.24 | -0.31 | -0.24 | -0.27 | -0.33 | -0.34 | -0.33 | -0.34 |
| Surprise | 0.03 | 0.03 | 0.09 | 0.01 | 0.07 | 0.11 | 0.01 | 0.05 | 0.04 | 0.02 | 0.03 | -0.01 |
| Surprise Percentage | 23.0769% | 18.75% | 50% | 6.25% | 29.1667% | 35.4839% | 4.1667% | 18.5185% | 12.1212% | 5.8824% | 9.0909% | -2.9412% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ADPT
2026-08-04 23:10:18
Adaptive Biotechnologies (ADPT) has issued $345 million in 0% convertible senior notes due 2031, using part of the proceeds to repurchase revenue interests and common stock. The company reported a Q2 2026 revenue of $71.6 million, an increase from the previous year, driven by MRD services, but also a widened net loss of $39.8 million. ADPT plans to separate its MRD and Immune Medicine businesses by the end of 2026, focusing Immune Medicine on its TCR-antigen dataset and target discovery.
2026-08-04 20:12:45
Adaptive Biotechnologies Corp (ADPT) reported Q2 2026 financial results, with revenue reaching $71.6 million, an increase from $58.9 million in the previous year. The company recorded a net loss of $(39.8) million and a diluted loss per share of $(0.25). Key drivers included a significant rise in minimal residual disease (MRD) revenue, while Immune Medicine revenue declined due to the termination of a collaboration, leading to a planned repositioning of that business segment.
2026-08-04 07:39:09
Susan Bobulsky, CCO of Adaptive Biotechnologies (NASDAQ:ADPT), sold
2026-08-03 23:39:09
This article from Investing.com announces the filing of Form 4 for Adaptive Biotechnologies Corp on August 3rd. Form 4 is a document filed with the SEC to report changes in beneficial ownership of a company's securities by insiders. The article includes the stock symbol ADPT and its intraday price performance, indicating a 2.39% increase.
2026-08-03 22:39:09
Adaptive Biotechnologies Corp's Chief Commercial Officer, Susan Bobulsky, sold 1,299 shares of common stock on July 30, 2026, at $24.00 per share, totaling $31,176. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 16, 2025. Following the sale, Bobulsky directly holds 399,989 shares in the company.
2026-08-01 07:11:18
Adaptive Biotechnologies Corp (ADPT) shares dropped 6.7%, and GuruFocus's GF Value suggests the stock is 125.0% overvalued at $22.57 compared to its estimated fair value of $10.03. Despite an above-average GF Score of 66/100, driven by strong growth and momentum ranks, its financial strength and profitability are concerning, and insider selling further signals caution for investors.
